- Piramal Pharma invests USD 85 million in CDMO expansion, maintenance, and capacity upgrades.
- Company aims to achieve over USD 2 billion in revenue by FY30 with targeted sector growth.
Piramal Pharma has earmarked approximately USD 85 million in capital expenditures for the current fiscal year to support initiatives including capacity expansion, maintenance, and de-bottlenecking at its contract development and manufacturing (CDMO) sites. The company has already invested USD 30 million in the first half of the fiscal year, Chairperson Nandini Piramal confirmed in an interview with PTI.
This investment forms part of Piramal’s broader growth strategy to reach over USD 2 billion in revenue by FY30, with specific CDMO, critical care, and consumer healthcare revenue targets. Approximately USD 30 million of this capex will address maintenance needs, while the remaining funds will support capacity expansion at facilities in Telangana and Dahej (Gujarat) as well as efforts to enhance efficiencies at multiple CDMO sites.
The CDMO division, Piramal Pharma Solutions (PPS), has already dedicated an additional USD 80 million to expanding its sterile injectables facility in Lexington, Kentucky, scheduled for completion by FY27. Commenting on Piramal’s targeted growth areas, Nandini Piramal stated, “We expect the capex this year to be at a similar level as last year, which is about USD 85 million.”
Beyond organic growth, Piramal is actively exploring acquisitions to meet its revenue objectives. The company has outlined ambitious targets for its divisions, projecting the CDMO vertical to achieve USD 1.2 billion by FY30, while critical care and consumer healthcare divisions are expected to reach USD 600 million and USD 200 million, respectively.
Overview of outsourcing trends 
